Dimensional Fund Advisors Increases Vertex Pharmaceuticals Stake

Institutional investor boosts holding in biotech firm by over 31%

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Dimensional Fund Advisors LP increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 31.4% during the 3rd quarter, according to a recent SEC filing. The fund now owns 783,586 shares of the pharmaceutical company's stock, worth approximately $306.9 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. Institutional investors closely watch the company's progress and financial performance, as it is seen as a bellwether for the broader pharmaceutical industry.

The details

According to the 13F filing, Dimensional Fund Advisors purchased an additional 187,359 shares of Vertex Pharmaceuticals during the third quarter. This increased the firm's total position to 783,586 shares, or approximately 0.31% of the company's outstanding stock. The purchase was part of Dimensional's strategy to boost its exposure to promising pharmaceutical companies.

  • Dimensional Fund Advisors increased its Vertex Pharmaceuticals holdings during the 3rd quarter of 2026.

The players

Dimensional Fund Advisors LP

A global investment management firm that provides a range of equity, fixed income, and alternative investment strategies to institutional and individual investors worldwide.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Dimensional Fund Advisors' increased stake in Vertex Pharmaceuticals underscores the biotech firm's strong position in the pharmaceutical industry and the confidence institutional investors have in its future growth prospects.